肝细胞癌中生长抑素受体的表达：预后及治疗考量

Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.

作者信息

Abdel-Rahman Omar, Lamarca Angela, Valle Juan W, Hubner Richard A

机构信息

Clinical Oncology DepartmentFaculty of Medicine, Ain Shams University, Cairo, EgyptDepartment of Medical OncologyThe Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UKUniversity of ManchesterManchester Academic Health Sciences Centre (MAHSC), Manchester, UK Clinical Oncology DepartmentFaculty of Medicine, Ain Shams University, Cairo, EgyptDepartment of Medical OncologyThe Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UKUniversity of ManchesterManchester Academic Health Sciences Centre (MAHSC), Manchester, UK.

出版信息

Endocr Relat Cancer. 2014;21(6):R485-93. doi: 10.1530/ERC-14-0389. Epub 2014 Oct 21.

DOI:10.1530/ERC-14-0389

PMID:25336571

Abstract

Sorafenib is the only systemic therapy to demonstrate a significant survival benefit over supportive care in robust randomised controlled trials for advanced hepatocellular carcinoma (HCC). In the context of an intense search for prognostic and predictive factors for response and efficacy of different systemic therapies (including sorafenib), a number of molecular targets have been identified, paving new avenues for potential therapeutic opportunities. Such molecular targets include somatostatin receptor (SSTR)-related alterations. In this review, we provide an overview of the various considerations relating to SSTRs as potentially novel prognostic and predictive biomarkers for HCC with special emphasis on the therapeutic potential of somatostatin analogues in HCC management.

摘要

在针对晚期肝细胞癌（HCC）的强有力的随机对照试验中，索拉非尼是唯一一种相较于支持性治疗能显著提高生存率的全身治疗药物。在积极探寻不同全身治疗（包括索拉非尼）的反应和疗效的预后及预测因素的背景下，已确定了多个分子靶点，为潜在的治疗机会开辟了新途径。此类分子靶点包括与生长抑素受体（SSTR）相关的改变。在本综述中，我们概述了与SSTRs作为HCC潜在的新型预后和预测生物标志物相关的各种考量因素，特别强调生长抑素类似物在HCC治疗中的潜在治疗价值。